modeling nature from nano to macro
Transfer &
Implementation
Patents
The multidisciplinary research of our unit of excellence is reflected by collaborations between different groups belonging to the field of applied physics, applied mathematics, electronic engineering, bioinformatics, medical bioengineering, organic and pharmaceutical chemistry, pharmacology, biotechnology or experimental oncology among others. This multidisciplinarity has allowed an innovative research and the transference through the protection of knowledge in order to facilitate the use, application and exploitation outside the academic field, either with other R & D institutions, the productive sector or society in general. We have generated technological innovations, patents or utility models and even the creation of new
start-up and new Spinoffs.
Moreover, several members of the Unit are enrolled in the “Technology Promoters” pilot program of the TTO (Technology Transfer Office) of the University of Granada. At the moment, they have attending skill training activities and initiatives in innovation management, technology transfer,
marketing and plan business that include topics about valorization and protection of research results, for instance, patents and utility models or the use of databases as sources of patent technology information.
We have a special interest in offering a necessary specialist training and invaluable expert mentoring for to develop and improve the valorization plan of the technology developed by the Unit. Also, we have as an objective for our PhD students and postdoctoral researcher to offer the possibility of establishing contact with businesses, entrepreneurs and investor that can give us the opportunity to elaborate an adequate commercialization/business plan that facilitates a possible spin-off /start-up creation. Definitely, we are convincing that our Mnat Unit must also require the transformation of scientific knowledge into a product that creates value in the society, increasing its success probabilities and facilitating access to markets for the benefit of the patients.
Polynucleotide for T cell specific transgen expression
Number: GENYO_19005
Date: 2020
CRISPNA, a new tool for genome editing and diagnosis
Number: P202031322
Date: 30/12/2020
Polinucleótido para expresión fisiológica en células T
Number: P202030955
Date: 2020
Composiciones para el tratamiento del cáncer, y específicamente de los sarcomas
Number: P202030148
Date: 2020
Método para predecir o pronosticar la respuesta al tratamiento del cáncer
Number: P202030147; WO2014122353
Date: 2020
Transistor FET reconfigurable con dopado dual
Number: P202030318
Date: 20/04/2020
Procedimiento de detección de radiación y partículas empleando un diodo semiconductor por modulación de bandas de energía
Number: P201831304
Date: 30/12/2018
Suspensiones Bimodales dentro del Límite Multidominio con Efecto Magneto-reológico Mejorado
Number: P201830726
Date: 18/07/2018
Polynucleotide for safer and more effective immunotherapies
Number: PCT/EP2019/081346; WO2020099572
Date: 2018
Licensed by LentiStem Biotech
Cancer treatment
Number: WO2017127892 A1; PCT/AU2017/050065
Date: 03/08/2017
Licensed by Propanc Biopharma, Inc
Ultrasonic low-frequency bioreactor as a selective therapy against cancer
Number: IPR-678
Date: 29/05/2017
Ultrasonic low frequency portable device for selective tumor therapy
Number: IPR-701
Date: 18/04/2017
Dispositivo transluminaly procedimiento para caracterización mecánica de estructuras
Number: P201730415
Date: 24/03/2017
Research &
Development Contracts
Using Engineered DNA to Assess Spatial and Temporal Variation in eDNA as a Measure of the Temporal and Spatial Variation of Biodiversity
Source of funding: UNITED STATES ARMY, U.S. ARMY CORP OF ENGINEERS through Cornell University USA
Reference: Contract OTRI (C4767-00)
PI: Francisco J. Rueda (UGR)
Funding: 83.660,00 $
Duration: 01/01/2021 - 19/09/2023
Bioimpresión 3D de cartílago y hueso con biotintas basadas en matriz descelularizada (dECM) para la regeneración de lesiones osteocondrales
Source of funding: Fundación Mutua Madrileña
Reference: FMM-AP17196-2019
PI: Elena López Ruiz
Funding: 120.000,00 €
Duration: 01/10/2019 - 30/09/2022
Valorización de plataforma de inmunoterapia
Source of funding: Fundación para la Innovación y la Prospectiva en Salud en España (FIPSE)
Reference: 3939-2
PI: Francisco Martín Molina
Funding: 29.000,00 €
Duration: 01/01/2021 - 31/12/2021
Development of biotinks and new marketable three-dimensional meshes for 3D bioprinting with application in regenerative medicine and cell therapy
Source of funding: Bioibérica (Barcelona)
Reference:
PI: Juan Antonio Marchal
Funding: 81.200,00 €
Duration: 01/01/2012 - 31/12/2021
Detección RApida de INmunoglobulinas (IgA secretora, IgGs e IgMs) para el diagnóstico precoz del SARS-COV-2 mediante un biosensor portátil de grafeno
Source of funding: Fondo Supera COVID, CRUE-Banco Santander
Reference: DRAINCOV
PI: Francisco Gamiz
Funding: 110.000,00 €
Duration: 01/08/2020 - 31/10/2021
Identifying tissue and allele-specific vulnerabilities in oncogenic KRAS signaling
Source of funding: Revolution Medicine Inc. (RevMED)
Reference:
PI: Lukas E Dow
Funding: 765.435,00 $
Duration: 01/07/2020 - 01/07/2021
Toxina HokD como nueva herramienta terapéutica frente a células madre cancerígenas derivadas de pacientes con cáncer de útero
Source of funding: Fundación Mutua Madrileña
Reference: FMM-AP16683-2017
PI: Houria Boulaiz Tassi
Funding: 121.690,00 €
Duration: 01/07/2017 - 30/06/2021
Tratamiento combinado con hiperoxia e inhibidores de PARP para contrarrestar la progresión tumoral mediada por hipoxia
Source of funding: Fundación Domingo Martínez
Reference:
PI: Javier Oliver Pozo
Funding: 100.000,00 €
Duration: 01/06/2019 - 31/05/2021
Dispositivo diagnostico 'Point of Care' para la deteccion RAPida de la COVID19
Source of funding: Fondo Supera COVID, CRUE-Banco Santander
Reference: RAPID-19
PI: Francisco Gamiz
Funding: 95.000,00 €
Duration: 15/06/2020 - 17/05/2021
Epi-transcriptomic small RNA modifications as predictive signatures for therapy response in Diffuse Large B cell Lymphoma
Source of funding: KWF - Dutch Cancer Society
Reference: rc476
PI: Danijela Koppers-Lalic, Daphne de Jong, Michael Hackenberg
Funding: 547.890,00 €
Duration: 01/03/2017 - 28/02/2021
Metabolic and Immunological Vulnerabilities of Colorectal Cancer
Source of funding: Stand Up to Cancer Foundation (SUC2)/ American Association of Cancer Research (AACR)
Reference: SU2C-AACR-DT22-17
PI: Lewis C Cantley (Weill Cornell Medicine)
Funding: 59.600,00 $ direct costs/year
Duration: 01/08/2019 - 31/07/2020
Desarrollo sintético de PRP y posterior validación del mismo
Source of funding: PROPANC BIOPHARMA (Australia)
Reference:
PI: Macarena Perán Quesada
Funding: 91.754,00 €
Duration: 09/05/2018 - 09/05/2020
Extinciones Invisibles: Pérdida de diversidad en zonas áridas de la Península Ibérica como consecuencia de la expansión de especies vegetales asociadas al ser humano (ExIn)
Source of funding: Fundación BBVA
Reference:
PI: José M. Gómez
Funding: 100.000,00 €
Duration: 01/01/2017 - 31/12/2019
Potential drug for colon cancer treatment designed against DNA Gquadruplex targets and selective through the use of glucose transporters
Source of funding: Worldwide Cancer Research (Scotland)
Reference: 16-0290
PI: Juan Carlos Morales, Co-Javier Oliver Pozo
Funding: 185.720,00 £
Duration: 01/01/2016 - 31/12/2018
Development of capacitorless 1T DRAM
Source of funding: Korea Institute of Science and Technology
Reference:
PI: Francisco Gamiz
Funding: 22.968,00 €
Duration: 01/01/2018 - 31/12/2018
Impact of hydropower damming on the physics of sub-arctic lakes
Source of funding: Energy Fund of the National Power Company in Iceland (Icelandic: Orkurannsóknasjóður Landsvirkjunar) through the University of Iceland
Reference: Contract OTRI (C3958)
PI: Francisco J. Rueda
Funding: 17.259,80 €
Duration: 04/04/2018 - 30/06/2018
Design of Smart Lubricants Using the Inverse Ferrofluid Approach
Source of funding: TOTAL
Reference: U16-055
PI: Juan de Vicente Álvarez-Manzaneda
Funding: 97.200,00 €
Duration: 01/06/2017 - 30/05/2018
Generation tools for the expression of proteins in cell lines
Source of funding: Px’Pharmaceutics (Grenoble, France)
Reference:
PI: Francisco Martin
Funding: 16.000,00 €
Duration: 12/02/2013 - 12/02/2018
Impact of hydropower damming on the physics of sub-arctic lakes
Source of funding: Energy Fund of the National Power Company in Iceland (Icelandic: Orkurannsóknasjóður Landsvirkjunar) through the University of Iceland
Reference: Contract FEUGR (C4334-00) with University of Granada
PI: Francisco J. Rueda
Funding: 23.074,95 €
Duration: 01/10/2016 - 31/12/2017
Determination of gene expression by microarray analyses after treatment with propanc formulations. Cell differentiation assays
Source of funding: Propanc Pty Ltd (Australia)
Reference:
PI: Juan Antonio Marchal, Macarena Perán
Funding: 29.400,00 €
Duration: 01/01/2015 - 31/12/2017
Shh morphogen gradient in the developing vertebrate neural tuve
Source of funding: Wellcome Trust
Reference: 080630/Z/06/A
PI: Prof. Karen Page, Dr. James Briscoe
Funding: 144.181,00 £
Duration: 01/02/2013 - 28/02/2017
Contrato de prestación de servicios
Source of funding: LentiStem Biotech (Granada)
Reference:
PI: Francisco Martin
Funding:
Duration: 01/01/2019 -
Contrato de licencia de explotación de las Patentes EP13382080.3, P201631406 y EP18380016.8
Source of funding: LentiStem Biotech (Granada)
Reference:
PI: Francisco Martin
Funding:
Duration: 01/06/2018 -
Associated Start-ups
& Spinoffs
Regemat 3D (http://www.regemat3d.com/)
PKR-Exogenetics SL (16/12/2016 - 31/12/2021)
Oritia & Boreas Wind Engineering (www.oritiayboreas.com)
LentiStem Biotech (http://www.lentistem.com)
CRISPNA Bio
